UB Paderborn / Katalog / Suche / in CDI

Clinical and Economic Impact of Ibalizumab for People With Multidrug-Resistant HIV in the United States

Journal of acquired immune deficiency syndromes (1999), 2020-02, Vol.83 (2), p.148

2020

Volltextzugriff (PDF)

Fit-for-purpose method development and validation for successful biomarker measurement

Pharmaceutical research, 2006-02, Vol.23 (2), p.312-328

2006

Volltextzugriff (PDF)

Clinical Impact and Cost-effectiveness of Genotype Testing at Human Immunodeficiency Virus Diagnosis in the United States

Clinical infectious diseases, 2020-03, Vol.70 (7), p.1353-1363

2020

Volltextzugriff (PDF)

Assessing the Impact of a Hospice and Palliative Medicine Mentored Clinical Shadowing Experience for First-Year Medical and Dental Students: A Pilot Study

American journal of hospice & palliative medicine, 2024-09, Vol.41 (9), p.1018-1028

2024

Volltextzugriff (PDF)

358 A Multi-arm Phase 1 Dose Escalation Study of Safety, Pharmacokinetics, and Pharmacodynamics of the Dual PI3K/mTOR Inhibitors PF-04691502 (oral) and PF-05212384 (IV) in Combination with the MEK Inhibitor PD-0325901 or Irinotecan in Patients with Advanced Cancer

European journal of cancer (1990), 2012-11, Vol.48, p.109-109

2012

Volltextzugriff (PDF)

Context-Aware Systems: A More Appropriate Response System to Hurricanes and Other Natural Disasters

Procedia computer science, 2014, Vol.36, p.21-26

Millham, R.

2014

Volltextzugriff (PDF)

Antitumor Activity in Melanoma and Anti-Self Responses in a Phase I Trial With the Anti-Cytotoxic T Lymphocyte–Associated Antigen 4 Monoclonal Antibody CP-675,206

Journal of clinical oncology, 2005-12, Vol.23 (35), p.8968-8977

2005

Volltextzugriff (PDF)

383 First-in-human study of PF-04691502, a small molecule oral dual inhibitor of PI3K and mTOR in patients with advanced cancer: Preliminary report on safety and pharmacokinetics

European journal of cancer supplements, 2010, Vol.8 (7), p.121-122

2010

Volltextzugriff (PDF)

387 First-in-human study of PF-05212384, a small molecule intravenous dual inhibitor of PI3K and mTOR in patients with advanced cancer: preliminary report on safety and pharmacokinetics

European journal of cancer supplements, 2010, Vol.8 (7), p.123-123

2010

Volltextzugriff (PDF)

104P Phase II Randomized Study of Pre-Operative Pf-04691502 Plus Letrozole Compared with Letrozole (L) In Patients with Estrogen Receptor-Positive, Her2-Negative Early Breast Cancer (Bc)

Annals of oncology, 2012-05, Vol.23, p.ii44

2012

Volltextzugriff (PDF)

Abstract OT2-3-02: Phase Ib/II study of an oral PI3K/mTOR inhibitor plus letrozole compared with letrozole (L) in pre-operative setting in patients with Estrogen Receptor-positive, HER2-negative early breast cancer (BC): Phase Ib preliminary data

Cancer research (Chicago, Ill.), 2012-12, Vol.72 (24_Supplement), p.OT2-3-02-OT2-3-02

2012

Volltextzugriff (PDF)

PH 1 Study of PI3KMTOR Inhibitors PF-04691502 or PF-05212384 + MEK Inhibitor PD-0325901 or Irinotecan in Advanced Cancer

Annals of oncology, 2013-11, Vol.24, p.ix42

2013

Volltextzugriff (PDF)

Phase (P) I study of PF-00299804 (PF) combined with figitumumab (FI; CP-751,871) in patients (pts) with advanced solid tumors (ASTs)

Journal of clinical oncology, 2010-05, Vol.28 (15_suppl), p.3026-3026

2010

Volltextzugriff (PDF)

PF-00299804 (PF299) in Asian patients (pts) with non-small cell lung cancer (NSCLC) refractory to chemotherapy (CT) and erlotinib (E) or gefitinib (G): A phase (P) I/II study

Journal of clinical oncology, 2010-05, Vol.28 (15_suppl), p.7599-7599

2010

Volltextzugriff (PDF)

Transforming voting paradigm - The shift from inline through online to mobile voting

2014 IEEE 6th International Conference on Adaptive Science & Technology (ICAST), 2014, p.1-7

2014

Volltextzugriff (PDF)

An investigation: reengineering sequential procedure-driven software into object-oriented event-driven software through UML diagrams

Proceedings - International Computer Software & Applications Conference, 2002, p.731-733

Millham, R.

2002

Volltextzugriff (PDF)

Preliminary activity and safety results from a phase I clinical trial of PF-00299804, an irreversible pan-HER inhibitor, in patients (pts) with NSCLC

Journal of clinical oncology, 2008-05, Vol.26 (15_suppl), p.8027-8027

2008

Volltextzugriff (PDF)

Ex vivo blood stimulation assay as a translational research tool in the development of the ticilimumab (CP-675,206)

Journal of clinical oncology, 2006-06, Vol.24 (18_suppl), p.2542-2542

2006

Volltextzugriff (PDF)

Creating context aware and adaptable Web services within a security framework

2013 International Conference on Computer Applications Technology (ICCAT), 2013, p.1-2

Millham, R.

2013

Volltextzugriff (PDF)

Phase lb/II study of an oral PI3K/mTOR inhibitor plus letrozole compared with letrozole (L) in pre-operative setting in patients with Estrogen Receptor-positive, HER2-negative early breast cancer (BC): Phase lb preliminary data

CANCER RESEARCH, 2012, Vol.72

2012

Volltextzugriff (PDF)

Determining granularity of independent tasks for reengineering a legacy system into an OO system

Proceedings 27th Annual International Computer Software and Applications Conference. COMPAC 2003, 2003, p.342-347

2003

Volltextzugriff (PDF)

History education through creative computing: Multi-dimensional views and interactive navigation of the historical development of a town

International Conference on Education and e-Learning Innovations, 2012, p.1-6

2012

Volltextzugriff (PDF)

Aspect-Oriented Security and Exception Handling within an Object Oriented System

2011 IEEE 35th Annual Computer Software and Applications Conference Workshops, 2011, p.321-326

2011

Volltextzugriff (PDF)

Domain Analysis in the Reengineering Process of a COBOL System

2009 33rd Annual IEEE International Computer Software and Applications Conference, 2009, Vol.2, p.293-299

2009

Volltextzugriff (PDF)

Digital cities: Nassau and Bologna - a study in contrasts

2009 IEEE Latin-American Conference on Communications, 2009, p.1-6

2009

Volltextzugriff (PDF)

Menü

Weitere Dienste

Einstellungen

Clinical and Economic Impact of Ibalizumab for People With Multidrug-Resistant HIV in the United States

Fit-for-purpose method development and validation for successful biomarker measurement

Clinical Impact and Cost-effectiveness of Genotype Testing at Human Immunodeficiency Virus Diagnosis in the United States

Assessing the Impact of a Hospice and Palliative Medicine Mentored Clinical Shadowing Experience for First-Year Medical and Dental Students: A Pilot Study

358 A Multi-arm Phase 1 Dose Escalation Study of Safety, Pharmacokinetics, and Pharmacodynamics of the Dual PI3K/mTOR Inhibitors PF-04691502 (oral) and PF-05212384 (IV) in Combination with the MEK Inhibitor PD-0325901 or Irinotecan in Patients with Advanced Cancer

Context-Aware Systems: A More Appropriate Response System to Hurricanes and Other Natural Disasters

Antitumor Activity in Melanoma and Anti-Self Responses in a Phase I Trial With the Anti-Cytotoxic T Lymphocyte–Associated Antigen 4 Monoclonal Antibody CP-675,206

383 First-in-human study of PF-04691502, a small molecule oral dual inhibitor of PI3K and mTOR in patients with advanced cancer: Preliminary report on safety and pharmacokinetics

387 First-in-human study of PF-05212384, a small molecule intravenous dual inhibitor of PI3K and mTOR in patients with advanced cancer: preliminary report on safety and pharmacokinetics

104P Phase II Randomized Study of Pre-Operative Pf-04691502 Plus Letrozole Compared with Letrozole (L) In Patients with Estrogen Receptor-Positive, Her2-Negative Early Breast Cancer (Bc)

Abstract OT2-3-02: Phase Ib/II study of an oral PI3K/mTOR inhibitor plus letrozole compared with letrozole (L) in pre-operative setting in patients with Estrogen Receptor-positive, HER2-negative early breast cancer (BC): Phase Ib preliminary data

PH 1 Study of PI3KMTOR Inhibitors PF-04691502 or PF-05212384 + MEK Inhibitor PD-0325901 or Irinotecan in Advanced Cancer

Phase (P) I study of PF-00299804 (PF) combined with figitumumab (FI; CP-751,871) in patients (pts) with advanced solid tumors (ASTs)

PF-00299804 (PF299) in Asian patients (pts) with non-small cell lung cancer (NSCLC) refractory to chemotherapy (CT) and erlotinib (E) or gefitinib (G): A phase (P) I/II study

Transforming voting paradigm - The shift from inline through online to mobile voting

An investigation: reengineering sequential procedure-driven software into object-oriented event-driven software through UML diagrams

Preliminary activity and safety results from a phase I clinical trial of PF-00299804, an irreversible pan-HER inhibitor, in patients (pts) with NSCLC

Ex vivo blood stimulation assay as a translational research tool in the development of the ticilimumab (CP-675,206)

Creating context aware and adaptable Web services within a security framework

Phase lb/II study of an oral PI3K/mTOR inhibitor plus letrozole compared with letrozole (L) in pre-operative setting in patients with Estrogen Receptor-positive, HER2-negative early breast cancer (BC): Phase lb preliminary data

Determining granularity of independent tasks for reengineering a legacy system into an OO system

History education through creative computing: Multi-dimensional views and interactive navigation of the historical development of a town

Aspect-Oriented Security and Exception Handling within an Object Oriented System

Domain Analysis in the Reengineering Process of a COBOL System

Digital cities: Nassau and Bologna - a study in contrasts

Suchergebnisse filtern